Abstract Title: currently loading...

information currently loading...

Loading ... please wait
timer Loading ... please wait

Free Paper Session 16: Vascular Diseases & Diabetic Retinopathy III

16:30 - 18:00 | 07 September | Room: Amphitheatre Havane

Back to Previous

16:30Real-world use of intravitreal aflibercept injections in diabetic macular edema: 1-year interim results of APOLLON
C. Dot France
16:36Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy
A. Abu El Asrar Saudi Arabia
16:42Multimodal imaging of the initial stages of diabetic retinopathy: different disease pathways in different patients
A. Santos Portugal
16:48Long term follow-up of patients with type 1 idiopathic macular telangiectasia
R. Schwartz United Kingdom
16:54Characterization of disease progression in the initial stages of retinopathy in diabetes type 2. A two-year longitudinal study
J. CunhaVaz Portugal
17:00Prognostic factors of functional response in major branch retinal vein occlusion
M. Vieira Portugal
17:06Real-life anatomical and visual acuity outcomes in treatment-naive patients treated with intravitreal aflibercept for diabetic macular oedema; 36 months results
M. Lukic United Kingdom
17:12Real-world effectiveness and safety study of fluocinolone acetonide intravitreal implant in persistent diabetic macular edema: a comparison of outcomes based on early versus late switching following an insufficient response to prior therapies
B. Oliveira Lopes Portugal
17:18Real-world outcomes in patients with macular oedema secondary to branch retinal vein occlusion receiving intravitreal anti-VEGF therapy in a UK public hospital setting
S. Ah-Moye United Kingdom
17:24Real-world outcomes in patients with macular oedema secondary to central retinal vein occlusion receiving intravitreal anti-VEGF therapy in a UK public hospital setting
P. Zalmay United Kingdom
17:30Comparison of intraoperative intravitreal dexamethasone implant (Ozurdex®) versus perioperative intravitreal anti-Vascular Endothelial Growth Factor (VEGF) in patients with diabetic macular oedema (DMO) undergoing cataract surgery
C. Putri United Kingdom
17:36Real-world outcomes with ranibizumab (RBZ) 0.5 mg initiation in French patients with visual impairment due to diabetic macular edema: 36-month results of the BOREAL-DME study
P. Massin France
17:42The USER Study: Long-term outcomes of patients with diabetic macular edema switched from dexamethasone implant to 0.2 µg/day Fluocinolone Acetonide Implant
F. Bandello Italy
17:48Changes in aqueous and vitreous inflammatory cytokine levels in retinal vein occlusion: a systematic review and meta-analysis
S. Minaker Canada
Back to Previous

Sign up to EURETINA

© EURETINA All rights reserved
Loading please wait